المؤلفون: Roberts, Janet¹, Desai, Nisha¹, McCoy, John², Goren, Andy^2,3

المصدر: Dermatologic Therapy. Jul2014, Vol. 27 Issue 4, p252-254. 3p.

مصطلحات موضوعية: *SULFOTRANSFERASES, *BALDNESS, *HAIR follicles, *MINOXIDIL

الشركة/الكيان: UNITED States. Food & Drug Administration

مستخلص: Two percent topical minoxidil is the only US Food and Drug Administration-approved drug for the treatment of female androgenetic alopecia ( AGA). Its success has been limited by the low percentage of responders. Meta-analysis of several studies reporting the number of responders to 2% minoxidil monotherapy indicates moderate hair regrowth in only 13-20% of female patients. Five percent minoxidil solution, when used off-label, may increase the percentage of responders to as much as 40%. As such, a biomarker for predicting treatment response would have significant clinical utility. In a previous study, Goren et al. reported an association between sulfotransferase activity in plucked hair follicles and minoxidil response in a mixed cohort of male and female patients. The aim of this study was to replicate these findings in a well-defined cohort of female patients with AGA treated with 5% minoxidil daily for a period of 6 months. Consistent with the prior study, we found that sulfotransferase activity in plucked hair follicles predicts treatment response with 93% sensitivity and 83% specificity. Our study further supports the importance of minoxidil sulfation in eliciting a therapeutic response and provides further insight into novel targets for increasing minoxidil efficacy. [ABSTRACT FROM AUTHOR]

المؤلفون: Chitalia, Jill¹ jillchitalia@gmail.com, Dhurat, Rachita¹, Goren, Andy^2,3, McCoy, John², Kovacevic, Maja³, Situm, Mirna⁴, Naccarato, Ty², Lotti, Torello³

المصدر: Dermatologic Therapy. Nov2018, Vol. 31 Issue 6, pN.PAG-N.PAG. 1p.

مصطلحات موضوعية: *SULFOTRANSFERASES, *BALDNESS treatment, *ENZYMES, *HAIR follicle diseases, *FAMILY history (Medicine), *DERMATOLOGY

مستخلص: Several studies have established that sulfotransferase enzyme activity in the outer root sheath of plucked hair follicles predicts response to topical minoxidil in the treatment of pattern hair loss. However, the prevalence of this enzyme activity among Indian patients has not been studied. Additionally, no reports in the literature characterize sulfotransferase activity based on sex, age, duration of hair loss, grade of hair loss, and family history. In this study we utilized a sulfotransferase activity assay first reported by Goren et al. We characterize the follicular sulfotransferase activity of 120 pattern hair loss patients visiting a dermatology outpatient clinic in India. Overall, 40.8% of patients with pattern hair loss had low levels of sulfotransferase. Surprisingly, 49.3% of men had low levels of sulfotransferase compared to 26.6% of women. No correlation was found between sulfotransferase activity and age, duration of hair loss, grade of hair loss, or family history. A sub‐analysis of patient reported outcomes (PRO) validated previous findings that sulfotransferase enzyme activity is a predictive marker for minoxidil response in pattern hair loss patients. [ABSTRACT FROM AUTHOR]

المؤلفون: Goren, Andy, Shapiro, Jerry, Roberts, Janet, McCoy, John, Desai, Nisha, Zarrab, Zoulikha, Pietrzak, Aldona, Lotti, Torello

المصدر: Dermatologic Therapy; Jan2015, Vol. 28 Issue 1, p13-16, 4p

مصطلحات موضوعية: BALDNESS, BALDNESS treatment, MINOXIDIL, SULFOTRANSFERASES, META-analysis, DIAGNOSIS, THERAPEUTICS

مستخلص: Clinical response to 5% topical minoxidil for the treatment of androgenetic alopecia ( AGA) is typically observed after 3-6 months. Approximately 40% of patients will regrow hair. Given the prolonged treatment time required to elicit a response, a diagnostic test for ruling out nonresponders would have significant clinical utility. Two studies have previously reported that sulfotransferase enzyme activity in plucked hair follicles predicts a patient's response to topical minoxidil therapy. The aim of this study was to assess the clinical utility and validity of minoxidil response testing. In this communication, the present authors conducted an analysis of completed and ongoing studies of minoxidil response testing. The analysis confirmed the clinical utility of a sulfotransferase enzyme test in successfully ruling out 95.9% of nonresponders to topical minoxidil for the treatment of AGA. [ABSTRACT FROM AUTHOR]

: Copyright of Dermatologic Therapy is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Paulo Müller Ramos, Rodney Sinclair, Andy Goren, Hélio Amante Miot

المصدر: Dermatologic Therapy. 33

مصطلحات موضوعية: Adult, Sulfotransferase, Sulfotransferase activity, business.industry, Administration, Topical, Alopecia, Dermatology, General Medicine, Middle Aged, Pharmacology, medicine.disease, Hair loss, Minoxidil, Humans, Medicine, Female, Sulfotransferases, business, Hair Follicle, Brazil, Aged, medicine.drug, Topical minoxidil

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2910687ca952f14091f38505d206826dTest
https://doi.org/10.1111/dth.13195Test

المؤلفون: Guangping Chen, Yimei Tan, Ralph M. Trüeb, Mirna Šitum, Andy Goren, Rachita Dhurat, Aseem Sharma, John McCoy, Sergio Vano-Galvan, Rodney Sinclair, Sandip Agrawal, Maja Kovacevic

المصدر: Dermatologic Therapy. 32

مصطلحات موضوعية: Adult, Male, Sulfotransferase, medicine.drug_class, Administration, Topical, Tretinoin, Dermatology, Pharmacology, Outer root sheath, Gene Expression Regulation, Enzymologic, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Follicular phase, Humans, Medicine, Retinoid, alopecia, minoxidil, tretinoin, integumentary system, business.industry, Alopecia, General Medicine, Hair follicle, Up-Regulation, medicine.anatomical_structure, Mechanism of action, Minoxidil, 030220 oncology & carcinogenesis, Female, Sulfotransferases, medicine.symptom, business, medicine.drug

الوصف: Minoxidil sulfate is the active metabolite required to exert the vasodilatory and hair growing effects of minoxidil. For hair growth, sulfotransferase enzymes expressed in outer root sheath of the hair follicle sulfonate minoxidil. The large intra- subject variability in follicular sulfotransferase was found to predict minoxidil response and thus explain the low response rate to topical minoxidil in the treatment of androgenetic alopecia. A method to increase minoxidil response would be of significant clinical utility. Retinoids have been reported to increase minoxidil response. The purported mechanism of action was retinoid modulation of skin permeation to minoxidil ; however, evidence to the contrary supports retinoids increase dermal thickness. In order to elucidate the effect of topical retinoids on minoxidil response, we studied the effect of topical tretinoin on follicular sulfotransferase. In this study, we demonstrate that topical tretinoin application influences the expression of follicular sulfotransferase. Of clinical significance, in our cohort, 43% of subjects initially predicted to be nonresponders to minoxidil were converted to responders following 5 days of topical tretinoin application. To the best of our knowledge, this is the first study to elucidate the interaction mechanism between topical minoxidil and retinoids and thus provides a pathway for the development of future androgenetic alopecia treatments.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba48dbc093949f59cfc56444c9200f51Test
https://doi.org/10.1111/dth.12915Test

المؤلفون: Rachita Dhurat, V Lukinovic Skudar, Torello Lotti, Andy Goren, Jerry Shapiro, John McCoy, Aseem Sharma, Maja Kovacevic, Mohamad Goldust, Rodney Sinclair, Mirna Šitum

المصدر: Dermatologic therapy. 31(6)

مصطلحات موضوعية: Drug, Adult, Male, Sulfotransferase, media_common.quotation_subject, Dermatology, Pharmacology, Administration, Cutaneous, Risk Assessment, 030207 dermatology & venereal diseases, 03 medical and health sciences, chemistry.chemical_compound, Young Adult, 0302 clinical medicine, Follicular phase, medicine, Humans, Drug Interactions, Prodrugs, Enzyme Inhibitors, alopecia, aspirin, minoxidil, media_common, Aspirin, business.industry, Alopecia, General Medicine, Prodrug, Hair follicle, medicine.anatomical_structure, Treatment Outcome, chemistry, Minoxidil, 030220 oncology & carcinogenesis, Sulfotransferases, business, Hair Follicle, Salicylic acid, medicine.drug

الوصف: Topical minoxidil is the only US FDA approved OTC drug for the treatment of androgenetic alopecia (AGA). Minoxidil is a pro‐drug converted into its active form, minoxidil sulfate, by the sulfotransferase enzymes in the outer root sheath of hair follicles. Previously, we demonstrated that sulfotransferase activity in hair follicles predicts response to topical minoxidil in the treatment of AGA. In the human liver, sulfotransferase activity is significantly inhibited by salicylic acid. Low‐dose OTC aspirin (75–81 mg), a derivative of salicylic acid, is used by millions of people daily for the prevention of coronary heart disease and cancer. It is not known whether oral aspirin inhibits sulfotransferase activity in hair follicles, potentially affecting minoxidil response in AGA patients. In the present study, we determined the follicular sulfotransferase enzymatic activity following 14 days of oral aspirin administration. In our cohort of 24 subjects, 50% were initially predicted to be responders to minoxidil. However, following 14 days of aspirin administration, only 27% of the subjects were predicted to respond to topical minoxidil. To the best of our knowledge, this is the first study to report the effect of low‐ dose daily aspirin use on the efficacy of topical minoxidil.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10f26a7c890eeae7466171881722afc0Test
https://pubmed.ncbi.nlm.nih.gov/30226287Test

المؤلفون: Goren, Andy, Castano, Juan Antonio, McCoy, John, Bermudez, Fernando, Lotti, Torello

المصدر: Dermatologic Therapy; May2014, Vol. 27 Issue 3, p171-173, 3p

مصطلحات موضوعية: BALDNESS, MINOXIDIL, SULFOTRANSFERASES, HAIR follicles, IMMUNOASSAY

مستخلص: Topical minoxidil is the most common drug used for the treatment of androgenetic alopecia ( AGA) in men and women. Although topical minoxidil exhibits a good safety profile, the efficacy in the overall population remains relatively low at 30-40%. To observe significant improvement in hair growth, minoxidil is typically used daily for a period of at least 3-4 months. Due to the significant time commitment and low response rate, a biomarker for predicting patient response prior to therapy would be advantageous. Minoxidil is converted in the scalp to its active form, minoxidil sulfate, by the sulfotransferase enzyme SULT1A1. We hypothesized that SULT1A1 enzyme activity in the hair follicle correlates with minoxidil response for the treatment of AGA. Our preliminary retrospective study of a SULT1A1 activity assay demonstrates 95% sensitivity and 73% specificity in predicting minoxidil treatment response for AGA. A larger prospective study is now under way to further validate this novel assay. [ABSTRACT FROM AUTHOR]

: Copyright of Dermatologic Therapy is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: John McCoy, Maja Kovacevic, Torello Lotti, Andy Goren, Jill Chitalia, Mirna Šitum, Ty Naccarato, Rachita Dhurat

المصدر: Dermatologic Therapy. 31:e12688

مصطلحات موضوعية: Adult, Male, Sulfotransferase, Adolescent, gubitak kose, minoksidil, sulfotranferaza, India, Physiology, Dermatology, Outer root sheath, Young Adult, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Follicular phase, Humans, Outpatient clinic, Medicine, Patient Reported Outcome Measures, Family history, Predictive marker, integumentary system, business.industry, Alopecia, General Medicine, Middle Aged, medicine.disease, Cross-Sectional Studies, Treatment Outcome, Hair loss, Minoxidil, 030220 oncology & carcinogenesis, Female, sense organs, Sulfotransferases, business, Biomarkers, Hair, medicine.drug

الوصف: Several studies have established that sulfotransferase enzyme activity in the outer root sheath of plucked hair follicles predicts response to topical minoxidil in the treatment of pattern hair loss. However, the prevalence of this enzyme activity among Indian patients has not been studied. Additionally, no reports in the literature characterize sulfotransferase activity based on sex, age, duration of hair loss, grade of hair loss, and family history. In this study we utilized a sulfotransferase activity assay first reported by Goren et al. We characterize the follicular sulfotransferase activity of 120 pattern hair loss patients visiting a dermatology outpatient clinic in India. Overall, 40.8% of patients with pattern hair loss had low levels of sulfotransferase. Surprisingly, 49.3% of men had low levels of sulfotransferase compared to 26.6% of women. No correlation was found between sulfotransferase activity and age, duration of hair loss, grade of hair loss, or family history. A sub-analysis of patient reported outcomes (PRO) validated previous findings that sulfotransferase enzyme activity is a predictive marker for minoxidil response in pattern hair loss patients.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3dba0b6e4871d28cea60f3b5bdc1906aTest
https://doi.org/10.1111/dth.12688Test

المؤلفون: Goren, A., Sharma, A., Dhurat, R., Shapiro, J., Sinclair, R., Situm, M., Kovacevic, M., Lukinovic Skudar, V., Goldust, M., Lotti, T., McCoy, J.

المصدر: Dermatologic Therapy; Nov2018, Vol. 31 Issue 6, pN.PAG-N.PAG, 1p

مصطلحات موضوعية: ASPIRIN, MINOXIDIL, DRUGS, SULFOTRANSFERASES, ENZYMES, SALICYLIC acid, CORONARY disease, CANCER

مستخلص: Topical minoxidil is the only US FDA approved OTC drug for the treatment of androgenetic alopecia (AGA). Minoxidil is a pro‐drug converted into its active form, minoxidil sulfate, by the sulfotransferase enzymes in the outer root sheath of hair follicles. Previously, we demonstrated that sulfotransferase activity in hair follicles predicts response to topical minoxidil in the treatment of AGA. In the human liver, sulfotransferase activity is significantly inhibited by salicylic acid. Low‐dose OTC aspirin (75–81 mg), a derivative of salicylic acid, is used by millions of people daily for the prevention of coronary heart disease and cancer. It is not known whether oral aspirin inhibits sulfotransferase activity in hair follicles, potentially affecting minoxidil response in AGA patients. In the present study, we determined the follicular sulfotransferase enzymatic activity following 14 days of oral aspirin administration. In our cohort of 24 subjects, 50% were initially predicted to be responders to minoxidil. However, following 14 days of aspirin administration, only 27% of the subjects were predicted to respond to topical minoxidil. To the best of our knowledge, this is the first study to report the effect of low‐dose daily aspirin use on the efficacy of topical minoxidil. [ABSTRACT FROM AUTHOR]

: Copyright of Dermatologic Therapy is the property of Hindawi Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Janet, Roberts, Nisha, Desai, John, McCoy, Andy, Goren

المصدر: Dermatologic therapy. 27(4)

مصطلحات موضوعية: Cohort Studies, Treatment Outcome, Administration, Topical, Minoxidil, Humans, Alopecia, Female, Sulfotransferases, Hair Follicle, Sensitivity and Specificity, Hair

الوصف: Two percent topical minoxidil is the only US Food and Drug Administration-approved drug for the treatment of female androgenetic alopecia (AGA). Its success has been limited by the low percentage of responders. Meta-analysis of several studies reporting the number of responders to 2% minoxidil monotherapy indicates moderate hair regrowth in only 13-20% of female patients. Five percent minoxidil solution, when used off-label, may increase the percentage of responders to as much as 40%. As such, a biomarker for predicting treatment response would have significant clinical utility. In a previous study, Goren et al. reported an association between sulfotransferase activity in plucked hair follicles and minoxidil response in a mixed cohort of male and female patients. The aim of this study was to replicate these findings in a well-defined cohort of female patients with AGA treated with 5% minoxidil daily for a period of 6 months. Consistent with the prior study, we found that sulfotransferase activity in plucked hair follicles predicts treatment response with 93% sensitivity and 83% specificity. Our study further supports the importance of minoxidil sulfation in eliciting a therapeutic response and provides further insight into novel targets for increasing minoxidil efficacy.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=pmid________::fbede593b2df5318e26e110f2e52bfeeTest
https://pubmed.ncbi.nlm.nih.gov/24773771Test